Clioquinol

From Wikipedia, the free encyclopedia - View original article

Clioquinol
Clioquinol.png
Systematic (IUPAC) name
5-chloro-7-iodo-quinolin-8-ol
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa682367
Pregnancy cat.C (US)
Legal statusPoM (UK); Rx (US)
Routestopical only
Identifiers
CAS number130-26-7 YesY
ATC codeD08AH30
D09AA10 (dressing) G01AC02 P01AA02 S02AA05
PubChemCID 2788
DrugBankDB04815
ChemSpider2686 YesY
UNII7BHQ856EJ5 YesY
KEGGD03538 YesY
ChEBICHEBI:74460 N
ChEMBLCHEMBL497 YesY
Chemical data
FormulaC9H5ClINO 
Mol. mass305.499 g/mol
 N (what is this?)  (verify)
 
Jump to: navigation, search
Clioquinol
Clioquinol.png
Systematic (IUPAC) name
5-chloro-7-iodo-quinolin-8-ol
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa682367
Pregnancy cat.C (US)
Legal statusPoM (UK); Rx (US)
Routestopical only
Identifiers
CAS number130-26-7 YesY
ATC codeD08AH30
D09AA10 (dressing) G01AC02 P01AA02 S02AA05
PubChemCID 2788
DrugBankDB04815
ChemSpider2686 YesY
UNII7BHQ856EJ5 YesY
KEGGD03538 YesY
ChEBICHEBI:74460 N
ChEMBLCHEMBL497 YesY
Chemical data
FormulaC9H5ClINO 
Mol. mass305.499 g/mol
 N (what is this?)  (verify)

Clioquinol (iodochlorhydroxyquin) is an antifungal drug and antiprotozoal drug. It is neurotoxic in large doses. It is a member of a family of drugs called hydroxyquinolines which inhibit certain enzymes related to DNA replication. The drugs have been found to have activity against both viral and protozoal infections.[1]

Antiprotozoal use[edit]

A 1964 report described the use of Clioquinol in both the treatment and prevention of shigella infection and Entamoeba histolytica infection in institutionalized individuals at Sonoma State Hospital in California. The report indicates 4000 individuals were treated over a 4-year period with few side effects.[2]

Several recently reported journal articles describing its use as an antiprotozoal include:

Clioquinol and SMON[edit]

Clioquinol's use as an antiprotozoal drug has been restricted or discontinued in some countries due to an event in Japan where over 10,000 people developed SMON (subacute myelo-optic neuropathy) between 1957 and 1970. The drug was used widely in many countries before and after the SMON event without similar reports.[6] As yet, no explanation exists as to why it produced this reaction, and some researchers have questioned whether clioquinol was the causative agent in the disease, noting that the drug had been used for 20 years prior to the epidemic without incident, and that the SMON cases began to reduce in number prior to the discontinuation of the drug.[7] Theories suggested have included improper dosing, the permitted use of the drug for extended periods of time,[8] and dosing which did not consider the smaller average stature of Japanese; however a dose dependant relationship between SMON development and clioquinol use was never found, suggesting the interaction of another compound. Researchers have also suggested the SMON epidemic could have been due to a viral infection with an Inoue-Melnick virus.[9]

Topical use[edit]

Clioquinol is a constituent of the prescription medicine Vioform, which is a topical antifungal treatment. It is also used in the form of a cream (and in combination with betamethasone) in the treatment of inflammatory skin disorders.

Use in neurodegenerative diseases[edit]

Research at UCSF indicates that clioquinol appears to block the genetic action of Huntington's disease in mice and in cell culture.[10]

Evidence from phase 2 clinical trials suggested that clioquinol could halt cognitive decline in Alzheimer's disease, possibly owing to its ability to act as a chelator for copper and zinc ions. This led to development of analogs including PBT2 as potential therapeutic compounds for the treatment of Alzheimer's disease.[11]

Recent animal studies have shown that clioquinol can reverse the progression of Alzheimer's, Parkinson's and Huntington's diseases. According to Dr. Siegfried Hekimi and colleagues at McGill's Department of Biology, clioquinol acts directly on a protein called Clk-1, often informally called “clock-1,” and might slow down the aging process. They theorize that this may explain the apparent ability of the drug to be effective in the above conditions, but warn against individuals experimenting with this drug.[1]

Continued use and manufacture around the world[edit]

CountryComments
United StatesIn August 2004, Prana Biotechnology, an Australian company and P.N Gerolymatos S.A (PNG) agreed to recognize each other's rights to market clioquinol in their respective territories, with PNG holding right for European territories, and Prana holding rights for US and Japan. Prana has performed research into the use of hydroxyquinolines drugs in the treatment of Alzheimers disease.
CanadaIn 2001, the Canadian company Paladin Labs bought the rights to market Vioform from Novartis. Vioform is licensed for use in Canada as a topical anti-fungal.
Netherlands2004 and 2005 reports describe use in treatment of Dientamoeba fragilis and Entamoeba histolytica infection.[4][4]
IndiaManufactured by Vishal Laboratories,and LASA laboratory pvt ltd (A Subsidiary of Omkar Speciality Chemicals ltd.) INDIA [12]

References[edit]

  1. ^ Rohde W, Mikelens P, Jackson J, Blackman J, Whitcher J, Levinson W (1976). "Hydroxyquinolines inhibit ribonucleic acid-dependent deoxyribonucleic acid polymerase and inactivate Rous sarcoma virus and herpes simplex virus". Antimicrob. Agents Chemother. 10 (2): 234–40. PMC 429727. PMID 185949. 
  2. ^ GHOLZ LM, ARONS WL (1964). "Prophylaxis And Therapy Of Amebiasis And Shigellosis With Iodochlorhydroxyquin". Am. J. Trop. Med. Hyg. 13: 396–401. PMID 14162901. 
  3. ^ Kager PA (2005). "[Outbreak of amoebiasis in a Dutch family; tropics unexpectedly nearby]". Nederlands tijdschrift voor geneeskunde (in Dutch; Flemish) 149 (1): 51–2; author reply 52–3. PMID 15651505. 
  4. ^ a b c Bosman DK, Benninga MA, van de Berg P, Kooijman GC, van Gool T (2004). "[Dientamoeba fragilis: possibly an important cause of persistent abdominal pain in children]". Nederlands tijdschrift voor geneeskunde (in Dutch; Flemish) 148 (12): 575–9. PMID 15074181. 
  5. ^ Masters DK, Hopkins AD (1979). "Therapeutic trial of four amoebicide regimes in rural Zaire". The Journal of tropical medicine and hygiene 82 (5): 99–101. PMID 226725. 
  6. ^ Wadia NH (1984). "SMON as seen from Bombay". Acta Neurol. Scand., Suppl. 100: 159–64. PMID 6091394. 
  7. ^ Meade TW (1975). "Subacute myelo-optic neuropathy and clioquinol. An epidemiological case-history for diagnosis". British journal of preventive & social medicine 29 (3): 157–69. PMC 478909. PMID 127638. 
  8. ^ Takasu T (2003). "[SMON--a model of the iatrogenic disease]". Rinsho Shinkeigaku (in Japanese) 43 (11): 866–9. PMID 15152488. 
  9. ^ Ito M, Nishibe Y, Inoue YK (1998). "Isolation of Inoue-Melnick virus from cerebrospinal fluid of patients with epidemic neuropathy in Cuba". Arch. Pathol. Lab. Med. 122 (6): 520–2. PMID 9625419. 
  10. ^ Nguyen T, Hamby A, Massa SM (2005). "Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model". Proc. Natl. Acad. Sci. U.S.A. 102 (33): 11840–5. doi:10.1073/pnas.0502177102. PMC 1187967. PMID 16087879. 
  11. ^ Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta.
  12. ^ Herlekar, Omkar. "Clioquinol manufacturers India". Lasa labs. Retrieved 12 March 2013.